Prolymphocytic Leukemia is a type of chronic leukemia. It's a cancer of the blood cells, specifically the lymphocytes. The main problem is that there are too many prolymphocytes, which are a specific kind of lymphocyte. This condition can happen on its own or develop from another type of chronic leukemia.
Every report comes from a Lived member, sent anonymously.
Have you tried Lemtrada (Alemtuzumab) for Prolymphocytic Leukemia?
Prolymphocytic leukemia (PLL) is a rare blood cancer of lymphocytes, the white blood cells that help the immune system recognize and fight infection. In PLL, one abnormal lymphocyte multiplies out of control, and its copies fill the blood, bone marrow and spleen. It makes up only about 2% of the cancers that arise from mature lymphocytes, and most people who develop it are over 60. There are two forms, named for the kind of lymphocyte involved. T-cell prolymphocytic leukemia (T-PLL) is the more common. It typically causes a very high white blood cell count, an enlarged spleen and often liver, mildly swollen lymph nodes, and low red blood cell and platelet counts, which can bring tiredness, breathlessness and easy bruising. Some people also develop a skin rash, swelling around the eyes or fluid around the lungs or abdomen. B-cell prolymphocytic leukemia (B-PLL) is rarer, and specialists now disagree about whether it is a separate disease. One major classification system still recognizes it, while the World Health Organization now places these cases under related conditions, such as chronic lymphocytic leukemia (CLL) that has changed into a faster-growing form. PLL is usually aggressive and needs specialist care. About a third of people with T-PLL are diagnosed during an early, quiet phase with few or no symptoms, but that phase eventually gives way to active disease.
In most people, what starts PLL is not known, and nothing a person did is known to cause it. Age is the clearest risk factor: it is mainly diagnosed in people in their 60s and 70s, and it is somewhat more common in men. In T-PLL, the leukemia cells almost always carry a chromosome rearrangement that switches on a growth-promoting gene called TCL1 (or a closely related gene), and most also lose a gene called ATM that normally helps repair damaged DNA. These changes develop within the leukemia cells during life rather than being inherited. The main exception is ataxia-telangiectasia, a rare inherited condition caused by changes in the ATM gene, in which T-PLL can appear as early as adolescence. Some cases with the B-cell pattern develop when an existing chronic lymphocytic leukemia transforms into a more aggressive form.
PLL is usually first suspected when a blood count shows a very high lymphocyte count, often above 100,000 cells per microliter. Treatment, by contrast, aims to bring that count below about 4,000. A physical exam and scans such as CT check the size of the spleen, liver and lymph nodes. The diagnosis is usually made from a blood sample. A specialist examines the cells under a microscope, and flow cytometry, a test that reads the markers on each cell's surface, shows whether they are T cells or B cells and whether they all descend from a single abnormal cell. Chromosome tests, including FISH (a technique that lights up specific chromosome changes), look for the rearrangement that defines most T-PLL. International criteria for T-PLL require a large population of these cells, proof that they come from one clone, and, in most cases, that characteristic chromosome change. A blood test for human T-lymphotropic virus type 1 (HTLV-1), a virus that causes a different T-cell leukemia, helps rule that out. A bone marrow biopsy is not always needed for the diagnosis but helps confirm a complete response after treatment. Because several other leukemias and lymphomas, including CLL, mantle cell lymphoma and Sezary syndrome, can look similar, no single test settles the diagnosis; it rests on putting all of these results together.
Treatment depends on which form a person has, whether the disease is active and how fit they are for intensive therapy. Not everyone needs treatment right away. People with T-PLL found in its quiet phase, without symptoms, usually have their blood counts checked regularly instead, because starting treatment early has not been shown to help. Treatment begins once the disease becomes active: symptoms such as fatigue, fevers, drenching night sweats or weight loss; an enlarged spleen, liver or lymph nodes causing symptoms; falling red cell or platelet counts; skin or other organ involvement; or a lymphocyte count that is climbing quickly, for example doubling within six months. For active T-PLL, the standard first treatment is alemtuzumab, a monoclonal antibody (a lab-made antibody) that attaches to a marker called CD52 on the leukemia cells and destroys them. It is given into a vein, usually three times a week for up to about 12 weeks, and works noticeably better that way than as an injection under the skin. Most people respond, often with their blood counts returning to normal, but responses usually last months rather than years. Standard chemotherapy works poorly in T-PLL and is not a first choice. Alemtuzumab strongly suppresses the immune system, so people take preventive antiviral and antibiotic medicines during treatment and for months afterward and have regular blood tests for cytomegalovirus (CMV), a common virus that can reactivate. In the United States, alemtuzumab for leukemia is supplied through a restricted program that the treating center arranges. For people who respond well and are fit enough, an allogeneic stem cell transplant, which replaces the blood-forming system with cells from a donor, is the only treatment that offers a realistic chance of long-term control or cure. It carries serious risks, including relapse and life-threatening complications, and only about a third to a half of people with T-PLL are well enough to have one. In published studies, roughly a third of those transplanted were alive long term. Newer targeted medicines, such as JAK inhibitors (which block a growth signal the leukemia cells rely on) and venetoclax, are being studied, often in clinical trials. For B-PLL and related B-cell forms, there is no agreed standard. Doctors generally treat it like high-risk CLL, using targeted pills such as Bruton tyrosine kinase (BTK) inhibitors or venetoclax, and consider a transplant for some people. Because the disease is rare and most evidence comes from small studies, a clinical trial is often worth discussing.
PLL is a serious diagnosis, and its course varies widely. For T-PLL, median survival in the current treatment era is under three years, and most people who respond to first treatment eventually relapse. People diagnosed in the quiet phase often stay stable for a year or two, occasionally longer, before treatment is needed. In a large US registry of people diagnosed with B-PLL, median survival was about 2.8 years overall, and about 7.8 years for those whose disease was slow enough to watch at first. These figures come from older or small studies and cannot predict any one person's course. Alemtuzumab treatment means frequent clinic visits for infusions and blood tests over several weeks, and lowered immunity can last six months or more after the last dose, so infection precautions continue well beyond treatment. A transplant is a major undertaking with its own recovery and long-term follow-up. After treatment, regular blood counts and exams watch for relapse. Because the disease often returns, many people find it helpful to talk with their care team early about goals and priorities, which can guide choices between intensive treatment, clinical trials and care focused on comfort and quality of life.
See a doctor if you have ongoing fatigue, unexplained weight loss, drenching night sweats, fullness or discomfort under the left ribs (a sign of an enlarged spleen), swollen glands or a new widespread rash, or if a blood test shows a high lymphocyte count. If your PLL is being watched without treatment, keep scheduled blood tests and report these symptoms between visits, since they can signal that the disease is becoming active. During treatment and for months afterward, call your care team right away for a fever of 100.5°F (38°C) or higher, chills, cough, mouth sores or other signs of infection, because infections in people with lowered immunity can become life-threatening quickly.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Prolymphocytic Leukemia is like, what's helped you, or ask the community a question.